DarioHealth Corp.
DRIONASDAQHealthcare● Active
$7.52
+$0.02(+0.26%)
Market Cap$54986308
P/E Ratio—
52W High$17.744
52W Low$5.935
DarioHealth Corp. (DRIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DRIO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.81
Est. -$1.09 · +25.7%
Revenue
$0.01B
Est. $0.01B · +2.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
DRIO reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.74 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$1.09 | -$0.81 | +25.7% | $0.01B | $0.01B | +2.4% |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$2.44 | -$0.80 | +67.2% | $0.01B | $0.01B | +3.0% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$2.63 | -$1.85 | +29.7% | $0.01B | $0.01B | -0.8% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$2.20 | -$2.40 | -9.1% | $0.01B | $0.01B | -24.2% |
| ▲ Q2 FY2025 | May 14, 2025 | -$1.40 | -$1.20 | +14.3% | $0.01B | $0.01B | -13.0% |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$3.20 | $0.20 | +106.3% | $0.01B | $0.01B | +0.4% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$3.60 | -$2.60 | +27.8% | $0.01B | $0.01B | +0.2% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.74
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$1.09
EPS Surpr.
+25.7%
Revenue
$0.01B
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
-$0.80
EPS Est.
-$2.44
EPS Surpr.
+67.2%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$1.85
EPS Est.
-$2.63
EPS Surpr.
+29.7%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$2.40
EPS Est.
-$2.20
EPS Surpr.
-9.1%
Revenue
$0.01B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$1.20
EPS Est.
-$1.40
EPS Surpr.
+14.3%
Revenue
$0.01B
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
$0.20
EPS Est.
-$3.20
EPS Surpr.
+106.3%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$2.60
EPS Est.
-$3.60
EPS Surpr.
+27.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.30 | $-0.29 | $-0.28 | 1 |
| Q3 FY2028 | $-0.45 | $-0.44 | $-0.43 | 1 |
| Q2 FY2028 | $-0.46 | $-0.45 | $-0.44 | 1 |
| Q1 FY2028 | $-0.36 | $-0.35 | $-0.34 | 1 |
| Q4 FY2027 | $-0.42 | $-0.41 | $-0.40 | 1 |
| Q3 FY2027 | $-0.64 | $-0.62 | $-0.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +25.7% | $8.68 | $8.10 | -6.68% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +67.2% | $8.93 | $8.24 | -7.73% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +29.7% | $11.75 | $9.92 | -15.57% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -9.1% | $10.06 | $8.57 | -14.81% |
| ▲ Q2 FY2025 | May 14, 2025 | +14.3% | $14.43 | $13.20 | -8.52% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +106.3% | $14.58 | $13.42 | -7.96% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +27.8% | $19.30 | $19.40 | +0.52% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +120.7% | $18.54 | $16.70 | -9.92% |
Q2 FY2026-6.68%
Report Date
May 13, 2026
EPS Beat/Miss
+25.7%
Price Before
$8.68
Price After
$8.10
Q1 FY2026-7.73%
Report Date
Mar 19, 2026
EPS Beat/Miss
+67.2%
Price Before
$8.93
Price After
$8.24
Q4 FY2025-15.57%
Report Date
Nov 13, 2025
EPS Beat/Miss
+29.7%
Price Before
$11.75
Price After
$9.92
Q3 FY2025-14.81%
Report Date
Aug 12, 2025
EPS Beat/Miss
-9.1%
Price Before
$10.06
Price After
$8.57
Q2 FY2025-8.52%
Report Date
May 14, 2025
EPS Beat/Miss
+14.3%
Price Before
$14.43
Price After
$13.20
Q1 FY2025-7.96%
Report Date
Mar 10, 2025
EPS Beat/Miss
+106.3%
Price Before
$14.58
Price After
$13.42
Q4 FY2024+0.52%
Report Date
Nov 7, 2024
EPS Beat/Miss
+27.8%
Price Before
$19.30
Price After
$19.40
Q3 FY2024-9.92%
Report Date
Aug 8, 2024
EPS Beat/Miss
+120.7%
Price Before
$18.54
Price After
$16.70
Avg Beat Reaction-7.98%
Avg Miss Reaction-14.81%
Beat Rate7 / 8 quarters
Largest Move-15.57% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DRIO ends December
DarioHealth Corp. (DRIO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.81 — beating the analyst consensus of $-1.09 by +25.7%. DRIO has beaten EPS estimates for 3 consecutive quarters. The next DRIO earnings date is expected around September 1, 2026.
Each quarter, investors track DRIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DRIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DRIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DRIO earnings · 5 questionsDarioHealth Corp.'s next earnings report is expected around September 1, 2026. DRIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DRIO historically reports after market close (AMC).
DRIO earnings datewhen is DRIO earningsDRIO next earnings datewhen does DRIO report earningsDRIO earnings calendar
▸ Source: FMP · DarioHealth Corp. SEC filings · US GAAP · DarioHealth Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026